Chemopreventive effect of nonsteroidal anti-inflammatory drugs on the development of a new colorectal polyp or adenoma in a high-risk population: A meta-analysis

被引:1
作者
Kanik, EA
Canbaz, H
Colak, T
Aydin, S
机构
[1] Mersin Univ, Dept Biostat, Tip Fak Dekanlik Binasi, TR-33169 Mersin, Turkey
[2] Mersin Univ, Dept Gen Surg, TR-33169 Mersin, Turkey
来源
CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL | 2004年 / 65卷 / 04期
关键词
aspirin; colorectal adenoma; colorectal cancer; meta-analysis; NSAIDs; relative risk;
D O I
10.1016/j.curtheres.2004.06.001
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Background: Although many experimental, epidemiologic, and clinical studies have suggested that aspirin or other nonsteroidal anti-inflammatory drugs (NSAIDs) are effective in reducing and preventing colorectal adenomas, randomized, controlled trials (RCTs) are still being carried out to obtain statistically reliable results. Objective: The aim of this meta-analysis was to review long-term, prospective RCTs investigating the effect of NSAIDs on the relative risk (RR) for developing 1 new colorectal polyp or adenoma in a high-risk population. Methods: We conducted a comprehensive search of MEDLINE, PubMed, and other electronic databases (including Inter-Science, Science Direct, Ebsco, Synergy, and Proquest) (key terms: nonsteroidal anti-inflammatory drugs, aspirin, colorectal, and polyps; years: 1974-2004) for English-language articles. Eligible studies were analyzed in terms of demographic data, adverse effects, and effect of NSAIDs on the RRs. Results: Four long-term, prospective RCTs were used in the statistical analysis. A total of 2069 high-risk patients were enrolled; 1880 patients completed the studies, and 1127 were in active-treatment groups (aspirin 81-325 mg/d or sulindac 150-300 mg/d). Our meta-analysis of these studies revealed that the overall RR for developing 1 new colorectal polyp or adenoma was significantly reduced by using aspirin or other NSAIDs (RR = 0.809; 95% CI, 0.718-0.912). Conclusions: The results of this meta-analysis suggest that regular use of aspirin 81 to 325 mg/d or sulindac 150 to 300 mg/d for greater than or equal to1 year was associated with a decrease in the RR for developing greater than or equal to1 new colorectal polyp or adenoma to 0.80 (95% CI, 0.718-0.912) in patients at high risk. Copyright (C) 2004 Excerpta Medica, Inc.
引用
收藏
页码:345 / 352
页数:8
相关论文
共 29 条
  • [1] A randomized trial of aspirin to prevent colorectal adenomas
    Baron, JA
    Cole, BF
    Sandler, RS
    Haile, RW
    Ahnen, D
    Bresalier, R
    McKeown-Eyssen, G
    Summers, RW
    Rothstein, R
    Burke, CA
    Snover, DC
    Church, TR
    Allen, JI
    Beach, M
    Beck, GJ
    Bond, JH
    Byers, T
    Greenberg, ER
    Mandel, JS
    Marcon, N
    Mott, LA
    Pearson, L
    Saibil, F
    van Stolk, RU
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (10) : 891 - 899
  • [2] Daily soluble aspirin and prevention of colorectal adenoma recurrence: One-year results of the APACC trial
    Benamouzig, R
    Deyra, J
    Martin, A
    Girard, B
    Jullian, E
    Piednoir, B
    Couturier, D
    Coste, T
    Little, J
    Chaussade, S
    [J]. GASTROENTEROLOGY, 2003, 125 (02) : 328 - 336
  • [3] APACC, a French prospective study on aspirin efficacy in reducing colorectal adenoma recurrence: design and baseline findings
    Benamouzig, R
    Yoon, H
    Little, J
    Martin, A
    Couturier, D
    Deyra, J
    Coste, T
    Chaussade, S
    [J]. EUROPEAN JOURNAL OF CANCER PREVENTION, 2001, 10 (04) : 327 - 335
  • [4] PROBLEMS INDUCED BY META-ANALYSES
    CHALMERS, TC
    [J]. STATISTICS IN MEDICINE, 1991, 10 (06) : 971 - 980
  • [5] Bias in meta-analysis detected by a simple, graphical test
    Egger, M
    Smith, GD
    Schneider, M
    Minder, C
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 1997, 315 (7109): : 629 - 634
  • [6] The MEK/ERK pathway mediates COX-2-selective NSAID-induced apoptosis and induced COX-2 protein expression in colorectal carcinoma cells
    Elder, DJE
    Halton, DE
    Playle, LC
    Paraskeva, C
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2002, 99 (03) : 323 - 327
  • [7] TREATMENT OF COLONIC AND RECTAL ADENOMAS WITH SULINDAC IN FAMILIAL ADENOMATOUS POLYPOSIS
    GIARDIELLO, FM
    HAMILTON, SR
    KRUSH, AJ
    PIANTADOSI, S
    HYLIND, LM
    CELANO, P
    BOOKER, SV
    ROBINSON, CR
    OFFERHAUS, GJA
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1993, 328 (18) : 1313 - 1316
  • [8] Primary chemoprevention of familial adenomatous polyposis with sulindac
    Giardiello, FM
    Yang, VW
    Hylind, LM
    Krush, AJ
    Petersen, GM
    Trimbath, JD
    Piantadosi, S
    Garrett, E
    Geiman, DE
    Hubbard, W
    Offerhaus, GJA
    Hamilton, SR
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (14) : 1054 - 1059
  • [9] ASPIRIN AND THE RISK OF COLORECTAL-CANCER IN WOMEN
    GIOVANNUCCI, E
    EGAN, KM
    HUNTER, DJ
    STAMPFER, MJ
    COLDITZ, GA
    WILLETT, WC
    SPEIZER, FE
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1995, 333 (10) : 609 - 614
  • [10] ASPIRIN USE AND THE RISK FOR COLORECTAL-CANCER AND ADENOMA IN MALE HEALTH-PROFESSIONALS
    GIOVANNUCCI, E
    RIMM, EB
    STAMPFER, MJ
    COLDITZ, GA
    ASCHERIO, A
    WILLETT, WC
    [J]. ANNALS OF INTERNAL MEDICINE, 1994, 121 (04) : 241 - 246